Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00110253 · ClinicalTrials.gov registry record · Phase 3

Duration of Skin Numbing Effect Created by the S-Caine™ Peel

A Phase 3 study of Pain, sponsored by ZARS Pharma.

Completed
Registry status
Phase 3
Development phase
40
Enrollment target
1
Study location

NCT00110253: Completed Phase 3 study of Pain, sponsored by ZARS Pharma.

NCT00110253 is a Phase 3 study of Pain that has completed, run by ZARS Pharma. The registered enrollment target is 40 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00110253, a Phase 3 study of Pain, has completed, sponsored by ZARS Pharma.

COMPLETED
Registry status
Phase 3
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes.

Primary Outcome

The duration of anesthesia was defined as the difference between the onset and end of anesthesia. If there was no onset of anesthesia, the duration was defined as zero. Onset of anesthesia was defined as the first time that the number of painful pinpricks was 2 or less (out of 5) for 2 consecutive time points. For subjects/treatments with onset of anesthesia, the end of anesthesia was defined as the first time after onset when the number of painful pinpricks was 3 or more for 2 consecutive time

Conditions Studied

Interventions

  • DRUG S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)

Study Locations (1)

California

  • Radiant Research - San Diego

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2005-06
Est. Completion 2005-06
Phase Phase 3
ZARS Pharma

23 total trials

What the finished NCT00110253 record still lists

NCT00110253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%) is the first listed.

NCT00110253 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00110253 about?

NCT00110253 is a clinical study titled "Duration of Skin Numbing Effect Created by the S-Caine™ Peel". S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes.

What is the current status of trial NCT00110253?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2005-06. Estimated completion is 2005-06.

What conditions does trial NCT00110253 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT00110253?

The interventions under investigation include: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%) (DRUG).

Who is sponsoring clinical trial NCT00110253?

This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00110253 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00110253's enrollment target sits among peer trials

40 282nd of 374 higher than 85 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00110253, the US trial registry maintained by the National Library of Medicine. NCT00110253 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.